OptiNose jumps 60% as chronic sinus treatment meets main goals in study

OptiNose

07/03/2022 12:48

** Shares of specialty pharma co  OPTN.O  rise as much as
60% to $4.30 before the bell
    ** Co says its lead drug-device, xhance, for treatment of
chronic sinus met both main goals in a late-stage study
 urn:newsml:reuters.com:*:nGNXbLf2hG
    ** If premarket gains stick through regular trading, stock
could hit hit its highest in over a year
    ** Chronic sinusitis, is a condition in which cavities
around nasal passages are inflamed and swollen for at least 12
weeks, for which there are currently no FDA-approved treatments
    ** XHANCE is already approved in the U.S. for treatment of
nasal polyps, a condition which causes swelling of nasal lining
    ** OPTN plans to report results from its second late-stage
study of XHANCE in chronic sinus in Q2
    ** Up to Friday's close, stock up ~68% YTD

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))